Myrelez (Lanreotide)

Lanreotide mimics natural somatostatin and binds to somatostatin receptors (mainly subtypes 2 and 5) on endocrine cells. This binding inhibits adenylate cyclase, lowers cyclic AMP, and suppresses the release of growth hormone, insulin, glucagon, gastrin and other peptides, thereby controlling hormone‑driven disease processes.

The specific dose and dosing interval of Myrelez are determined by the prescribing clinician based on the patient’s condition, disease severity and response to therapy. Healthcare providers select the appropriate strength and administration schedule in accordance with approved labeling and clinical guidelines.

Safety of lanreotide in pregnancy and lactation has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Myrelez, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Myrelez (lanreotide) and other agents such as octreotide share the same mechanism of receptor activation but differ in formulation and dosing frequency. Lanreotide is available as a long‑acting injectable that can be administered every 4–8 weeks, whereas octreotide often requires more frequent dosing, which may influence convenience and adherence.

Myrelez should be stored at 2–8 °C in a refrigerator, protected from light and moisture. Do not freeze the product or shake the vial vigorously. If temporary storage at controlled room temperature is unavoidable, use it within the time frame specified in the product labeling.

Myrelez is given by subcutaneous injection, typically using a prefilled syringe or autoinjector. The injection site is rotated among the abdomen, thigh or upper arm to reduce local irritation. Administration is performed by a qualified healthcare professional or trained patient following aseptic technique.

Serious adverse events reported with lanreotide include gallbladder disease (such as biliary sludge or cholelithiasis), acute pancreatitis, severe hyperglycemia that may require medical intervention, and rare anaphylactic reactions. Patients should be monitored for symptoms of these conditions and seek immediate medical attention if they occur.

Myrelez is contraindicated in individuals with known hypersensitivity to lanreotide or any of the excipients in the formulation. Caution is also advised for patients with severe renal impairment, uncontrolled diabetes, or existing gallbladder disease, and it should be avoided in these situations unless the prescribing physician determines that benefits outweigh risks.